Mobile website
Archive > Volume 24 Issue 6 > 2017,24(6):660-664. DOI:10.3872/j.issn.1007-385X.2017.06.015 Prev Next
Clinical Research
Efficacy of chemotherapy combined with autologous tumor antigen load dendritic cellscytokine induced killer cell therapy in the treatment of gastric cancer patients after surgery
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore the clinical efficacy and safety of chemotherapy combined with autologous tumor antigen load dendritic cellscytokininduced killer (AgDCCIK) cell therapy in the treatment of gastric cancer patients after D2 surgery. Methods: The present study enrolled 60 patients with gastric cancer in progressive stage (stage Ⅱ, stage Ⅲ) who underwent D2 surgery in the department of gastrointestinal surgery, Jingzhou Central Hospital during January, 2013 to March, 2014. The patients were randomly divided into chemotherapy group (FOLFOX regimen for 6 cycles) and combined treatment group (FOLFOX chemotherapy for 6 cycles+AgDCCIK cell therapy). The patients were followed up for two years. The twoyear overall survival (OS) and progression free survival (PFS), the levels of T cell subsets in the peripheral blood (CD3+ , CD4+, CD8+, CD3+CD56+), quality of life and adverse reactions were evaluated in the two groups. Results: Compared to the chemotherapy group, the twoyear OS and PFS were significantly higher in combined treatment group (both P<005). There was no significant difference in level of T cell subsets in peripheral blood of patients between pretreatment and posttreatment in combined treatment group (P>0.05); however, the level of T cell subsets in the peripheral blood of patients of chemotherapy group decreased significantly (P<0.05), and it was significant lower than that of combined treatment group (P<0.05). Compared to the chemotherapy group, the combined treatment group had higher quality of life (\[7.25±1.56\] vs \[5.54±1.27\], P<0.05) and lower adverse reactions (100% vs 20.0%, P<0.05). Conclusion: AgDCCIK cell therapy in combination with chemotherapy, compared with chemotherapy alone, can obviously increase the twoyear OS and PFS, protect the immune function of patients, reduce the adverse reactions and improve quality of life for gastric cancer patients.
Keywords:
Project Supported:
Project supported by the Science and Technology Support Project of Jingzhou City (No. 2014048)
Clc Number:
